{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-041735","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.485668+00:00","generated_at":"2026-06-02T04:18:34.235834+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TherapeuticsMD Q1 net loss narrows to $0.8M; strategic alternatives review ongoing","bullets":["Net loss from continuing operations of $0.8M ($0.07/share) vs. $2.3M ($0.24/share) in Q1 2023.","Gross license royalties of $1.2M under Mayne License Agreement; net royalties: $0.3M revenue and $0.3M other income.","Operating expenses down 52.8% to $1.5M from $3.1M, driven by transition to royalty-based model.","Cash and equivalents $4.3M at Mar 31, 2024; continues evaluating strategic alternatives including M&A or sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-041735","json":"https://secwatch.observer/filing/0001213900-24-041735.json","markdown":"https://secwatch.observer/filing/0001213900-24-041735.md","text":"https://secwatch.observer/filing/0001213900-24-041735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390024041735/0001213900-24-041735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390024041735/ea0205779-8k_therape.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:18:34.235834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68b114804133c1da3d0343b2994d9eff6209055e","claim":"TherapeuticsMD, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.3 million, net income $(0.8) million, EPS $(0.07) per basic and diluted common share.","evidence_excerpt":"in revenue, net and other income based on the proportion of the sales from each of our licensed products. Based on sales of our licensed products, the Company recognized $0.3 million in revenue, net, and approximately $0.3 million in other income in the three months ended March 31, 2024 related to net license royalties. Total Operating Expenses from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000121390024041735/0001213900-24-041735-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.3 million"},{"label":"Net income","value":"$(0.8) million"},{"label":"EPS","value":"$(0.07) per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}